Evidence map›Paper›PMID 40274730›Full record

ArticleReproductive sciences (Thousand Oaks, Calif.)2025

From Dominant Assumptions to Recessive Trait: Rethinking BMP15 in Ovarian Dysfunction.

Bérénice Hervé, Camille Verebi, Marion Bonnier, Pénélope Jordan, Diana Stroe, Charlotte Voisin, Diane Hill, Cynthia Sarfati, Maud Lansiaux, Daniel Terral and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Reproductive sciences (Thousand Oaks, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Bérénice HervéService de Médecine Génomique Des Maladies de Système Et d'Organe, Hôpital Cochin, APHP.Centre Université de Paris Cité, 123 Boulevard de Port-Royal, 75014, Paris, France.
Camille VerebiService de Médecine Génomique Des Maladies de Système Et d'Organe, Hôpital Cochin, APHP.Centre Université de Paris Cité, 123 Boulevard de Port-Royal, 75014, Paris, France.
Marion BonnierService de Gynécologie Médicale, APHP, Hôpital Robert Debré, 75, Paris, France.
Pénélope JordanService de Médecine Génomique Des Maladies de Système Et d'Organe, Hôpital Cochin, APHP.Centre Université de Paris Cité, 123 Boulevard de Port-Royal, 75014, Paris, France.
Diana StroeUnité de Gynécologie Médicale, APHP. Centre Université Paris Cité, Hôpital Cochin Port-Royal, 75014, Paris, France.
Charlotte VoisinUnité de Gynécologie Médicale, APHP. Centre Université Paris Cité, Hôpital Cochin Port-Royal, 75014, Paris, France.
Diane HillUnité de Gynécologie Médicale, APHP. Centre Université Paris Cité, Hôpital Cochin Port-Royal, 75014, Paris, France.
Cynthia SarfatiDépartement d'Endocrinologie et médecine de la reproduction, APHP. Sorbonne Université, Pitié-Salpêtrière Hospital, Center for Rare Endocrine and Gynecological Disorders, ERN-HCP, Paris, France.
Maud LansiauxService de Chirurgie Gynécologique Obstétrique, Centre Hospitalier Saint Joseph, Paris, France.
Daniel TerralService de Pédiatrie Médicale, CHU Clermont-Ferrand, Clermont Ferrand, France.
Anne BachelotDépartement d'Endocrinologie et médecine de la reproduction, APHP. Sorbonne Université, Pitié-Salpêtrière Hospital, Center for Rare Endocrine and Gynecological Disorders, ERN-HCP, Paris, France.
Jean Michel DupontService de Médecine Génomique Des Maladies de Système Et d'Organe, Hôpital Cochin, APHP.Centre Université de Paris Cité, 123 Boulevard de Port-Royal, 75014, Paris, France.
Sophie Christin-MaitreService d'endocrinologie, Diabétologie Et Médecine de La Reproduction, APHP. Sorbonne Université, Hôpital Saint-Antoine, 75012, Paris, France.
Geneviève Plu-BureauUnité de Gynécologie Médicale, APHP. Centre Université Paris Cité, Hôpital Cochin Port-Royal, 75014, Paris, France.
Thierry BienvenuService de Médecine Génomique Des Maladies de Système Et d'Organe, Hôpital Cochin, APHP.Centre Université de Paris Cité, 123 Boulevard de Port-Royal, 75014, Paris, France. thierry.bienvenu@inserm.fr.ORCID 0000-0002-5953-2728

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Approximately 1% of women experience premature ovarian insufficiency (POI) before the age of 40. Genetic factors play a significant role in the development of POI. The BMP15 gene is one of the first genes involved in POI. However, the pathogenicity and the penetrance of BMP15 variants still remain unclear. A cohort of 500 patients with POI/DOR (diminished ovarian reserve) underwent next generation sequencing of the entire coding region of the BMP15 gene. The frequency of each identified BMP15 variant was then compared with that of the general population, taking into account the ethnicity of each individual. Screening of the entire coding region of the BMP15 gene allowed us the identification of 11 different variants, including one pathogenic non-sense variant. A total of 54 patients with POI (10.8%) carried out at least one BMP15 variant. With regard to missense variants, we observed a significant overrepresentation of two missense variants (2/10 missense variants) in our 500 POI patients when compared to the general or specific ethnic subgroups. Of interest is the identification of one homozygous POI subject with a loss-of-function variant. The results of the segregation analysis indicated that this variant was inherited by the healthy mother (menarche at 16 years of age, and physiological menopause at 53 years of age) and by the father. This epidemiological study suggests that the majority of heterozygous missense variants could be considered as benign variants, while the homozygous loss-of-function variant could be considered as pathogenic variant. Several missense variants should be considered as variants of uncertain significance, conferring a moderate risk with probable partial and very low penetrance and/or expressivity. However, it should be noted that these variants are only deleterious in the compound heterozygous or homozygous status.

Indexed as

Bone Morphogenetic Protein 15Genes, RecessivePrimary Ovarian InsufficiencyAdultFemaleGenetic Predisposition to DiseaseHumansMiddle AgedMutation, MissenseYoung AdultBMP15 protein, humanBone Morphogenetic Protein 15BMP15PenetrancePremature ovarian insufficiency

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.